S

Southcoast Research Center | Miami, FL

Research site

(Unclaimed)

Location

1011 Sunnybrook Road, Suite 901, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Cenerimod

Permethrin

Itolizumab

Tofacitinib

Estradiol

Rimegepant

KZR-616

PF-07275315

Ritlecitinib

BHV-3000

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 17 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS-1)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Enrolling

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Cenerimod

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling

Atopic Dermatitis

Drug: PF-07264660

Drug: PF-07275315

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS OLE)

The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe sympto...

Invitation-only

Lupus Erythematosus, Systemic

Drug: Cenerimod